Nissay Asset Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $16M | Sell |
264,097
-2,821
| -1% | -$164K | 0.08% | 163 |
|
|
2025
Q4 | $14.4M | Buy |
266,918
+2,709
| +1% | +$130K | 0.07% | 171 |
|
|
2025
Q3 | $11.9M | Buy |
264,209
+1,885
| +0.7% | +$88K | 0.07% | 191 |
|
|
2025
Q2 | $12.1M | Buy |
262,324
+2,899
| +1% | +$142K | 0.07% | 192 |
|
|
2025
Q1 | $15.8M | Buy |
259,425
+2,203
| +0.9% | +$128K | 0.1% | 147 |
|
|
2024
Q4 | $14.8M | Sell |
257,222
-5,090
| -2% | -$284K | 0.09% | 156 |
|
|
2024
Q3 | $13.6M | Buy |
262,312
+6,152
| +2% | +$289K | 0.09% | 161 |
|
|
2024
Q2 | $10.6M | Buy |
256,160
+4,954
| +2% | +$222K | 0.07% | 179 |
|
|
2024
Q1 | $13.6M | Sell |
251,206
-9,162
| -4% | -$467K | 0.09% | 143 |
|
|
2023
Q4 | $13.4M | Buy |
260,368
+8,757
| +3% | +$460K | 0.11% | 127 |
|
|
2023
Q3 | $14.6M | Buy |
251,611
+6,124
| +2% | +$375K | 0.13% | 104 |
|
|
2023
Q2 | $15.7M | Sell |
245,487
-10,238
| -4% | -$687K | 0.14% | 100 |
|
|
2023
Q1 | $17.7M | Sell |
255,725
-10,465
| -4% | -$738K | 0.16% | 94 |
|
|
2022
Q4 | $19.2M | Sell |
266,190
-7,064
| -3% | -$533K | 0.18% | 91 |
|
|
2022
Q3 | $19.4M | Buy |
273,254
+4,045
| +2% | +$293K | 0.2% | 80 |
|
|
2022
Q2 | $20.7M | Buy |
269,209
+7,030
| +3% | +$535K | 0.21% | 81 |
|
|
2022
Q1 | $19.1M | Buy |
262,179
+3,921
| +2% | +$263K | 0.17% | 88 |
|
|
2021
Q4 | $16.1M | Buy |
258,258
+6,619
| +3% | +$388K | 0.12% | 107 |
|
|
2021
Q3 | $14.9M | Sell |
251,639
-4,788
| -2% | -$315K | 0.13% | 105 |
|
|
2021
Q2 | $17.1M | Buy |
256,427
+5,587
| +2% | +$364K | 0.15% | 94 |
|
|
2021
Q1 | $15.8M | Sell |
250,840
-6,447
| -3% | -$401K | 0.16% | 88 |
|
|
2020
Q4 | $16M | Sell |
257,287
-10,203
| -4% | -$627K | 0.24% | 87 |
|
|
2020
Q3 | $16.1M | Sell |
267,490
-36,391
| -12% | -$2.19M | 0.27% | 80 |
|
|
2020
Q2 | $17.9M | Sell |
303,881
-23,858
| -7% | -$1.43M | 0.35% | 74 |
|
|
2020
Q1 | $18.3M | Buy |
327,739
+20,257
| +7% | +$1.24M | 0.47% | 57 |
|
|
2019
Q4 | $19.7M | Buy |
307,482
+79,849
| +35% | +$4.57M | 0.44% | 52 |
|
|
2019
Q3 | $11.5M | Buy |
227,633
+1,886
| +0.8% | +$88.6K | 0.28% | 89 |
|
|
2019
Q2 | $10.2M | Buy |
225,747
+14,810
| +7% | +$690K | 0.26% | 96 |
|
|
2019
Q1 | $10.1M | Sell |
210,937
-46,366
| -18% | -$2.31M | 0.27% | 87 |
|
|
2018
Q4 | $13.4M | Sell |
257,303
-46,826
| -15% | -$2.52M | 0.41% | 60 |
|
|
2018
Q3 | $18.9M | Buy |
304,129
+8,544
| +3% | +$507K | 0.51% | 42 |
|
|
2018
Q2 | $16.4M | Buy |
295,585
+3,080
| +1% | +$166K | 0.48% | 49 |
|
|
2018
Q1 | $18.5M | Sell |
292,505
-3,239
| -1% | -$208K | 0.58% | 41 |
|
|
2017
Q4 | $18.1M | Buy |
+295,744
| New | +$18.5M | 0.55% | 44 |
|
Other funds holding BMY
VCM
VPM
Nissay Asset Management's BMY Position: Q1 2026 in Review
Nissay Asset Management reduced its Bristol-Myers Squibb (BMY) stake by 1.1% in Q1 2026, selling an estimated $164K and leaving 264,097 shares worth $16M. The position accounts for 0.08% of the portfolio, ranked #163.
Nissay Asset Management first reported a position in BMY in Q4 2017 and has held it in 34 quarters since. The position peaked at $20.7M in Q2 2022. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Nissay Asset Management held 264,097 shares of Bristol-Myers Squibb worth $16M as of Q1 2026.
- Nissay Asset Management sold 2,821 Bristol-Myers Squibb shares in Q1 2026, an estimated $164K.
- Bristol-Myers Squibb made up 0.08% of Nissay Asset Management's portfolio in Q1 2026, its #163 holding.
- Nissay Asset Management first reported a position in Bristol-Myers Squibb in Q4 2017 and has held it in 34 quarters since.
- Nissay Asset Management's Bristol-Myers Squibb position peaked at $20.7M in Q2 2022.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Nissay Asset Management's 13F filing for Q1 2026, filed 15 May 2026.